Clinical Trials

Alabama Oncology considers clinical research to be an important part of our overall mission, and we are proud to provide access to clinical trials as a part of your care.

If you think you might be interested in taking part in a clinical trial and would like to speak to someone for more information, please ask your physician or contact a clinical research coordinator at (205) 263-9746.

Please see the current list of studies we have available for our patients below:

Treatment Studies:

 

Lung

 

 Small Cell Lung Cancer

  • Henlius ASTRIDE: A Randomized, Open-label Study of Serplulimab Plus Chemotherapy (Carboplatin-Etoposide) in Comparison With Atezolizumab Plus Chemotherapy in Previously Untreated US Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ASTRIDE)

Non-Small Cell Lung Cancer

 

Breast

 

Triple Negative Breast Cancer

  • Gilead Ascent-05: Phase III Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05)

ER Positive, HER2 Negative:

  • AZ Cambria-1: A phase III open label randomizsed study to assess the efficacy and safety of switching to AZD9833 vs continuing standard endocrine therapy (aromatase inhibitor or tamoxifen) in Patients with HR+/HER2- early breast cancer and an intermediate or high risk of recurrence who have completed definitive locoregional therapy and at least 2 years of adjuvant endocrine therapy wihtout disease recurrence.
  • PUMA AL1 1201: A Study of Alisertib in Combination with Endocrine Therapy in Patients with HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer (ALISCA-Breast1)

Observational / Biomarker Studies:

 

Various Tumor types

 

Exact Sciences ES2021-05: Multi cancer early detection (MCED) test development for newly diagnosed or recurrent cancers https://www.exactsciences.com/Pipeline-and-Data/clinical-studies

Flatiron Health PRWS: Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers
https://clinicaltrials.gov/study/NCT06605404

MT3060: A biomarker study for Non-Small Cell Lung Cancer, Head and Neck Cancer, Triple Negative Breast Cancer, and Colorectal Cancer
https://mtgroupbio.com/

Tempus ARIES: A biobank registry for various tumor types
https://clinicaltrials.gov/study/NCT06207032

 

Lung

 

Tempus GEMINI: A biobank registry for Non-small cell lung cancer
https://clinicaltrials.gov/study/NCT05236114

 

Prostate

 

MT0282: Biomarker study for metastatic castration resistant prostate cancer (mCRPC) for patients starting a new qualifying line of treatment
https://mtgroupbio.com/

 

Lymphoma

 

Morphosys (INCYTE) RealMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination with Lenalidomide in Patients with Relapsed or Refractory DLBCL (Diffuse Large B cell Lymphoma) (realMIND)
https://clinicaltrials.gov/study/NCT04981795

 

Multiple Myeloma

 

Janssen 54767414NAP4002: A Pilot Prospective Observational Study to Evaluate an Electronic Health Record-Based Data Collection Infrastructure for Capturing Risk Factors for Severe and Fatal Infusion-related Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous)
https://classic.clinicaltrials.gov/ct2/show/NCT02497378